About Gap junction gamma-2 protein
Gap junction gamma-2 protein (GJC2) is a protein
from Homo sapiens identified by UniProt accession
Q5T442, 439 residues long.
MolForge cross-references it against 0 known binders and
77 disease associations.
Target properties
| Protein name | Gap junction gamma-2 protein |
| UniProt accession | Q5T442 |
| Gene | GJC2 |
| Organism | Homo sapiens |
| Length | 439 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (77)
Diseases linked to this target (Open Targets).
- Pelizaeus-Merzbacher-like disease due to GJC2 mutation · score 0.78
- Autosomal recessive spastic paraplegia type 44 · score 0.77
- hypomyelinating leukodystrophy 2 · score 0.73
- Milroy disease · score 0.71
- hereditary spastic paraplegia 44 · score 0.68
- lymphatic malformation 3 · score 0.62
- Spastic paraplegia · score 0.54
- genetic disorder · score 0.47
- Intellectual disability · score 0.34
- Abnormality of the nervous system · score 0.33
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q5T442-F1 | alphafold | PREDICTED | 67.05 | — |
Amino-acid sequence (439 residues)
MTNMSWSFLT RLLEEIHNHS TFVGKVWLTV LVVFRIVLTA VGGEAIYSDE QAKFTCNTRQ PGCDNVCYDA FAPLSHVRFW VFQIVVISTP SVMYLGYAVH RLARASEQER RRALRRRPGP RRAPRAHLPP PHAGWPEPAD LGEEEPMLGL GEEEEEEETG AAEGAGEEAE EAGAEEACTK AVGADGKAAG TPGPTGQHDG RRRIQREGLM RVYVAQLVAR AAFEVAFLVG QYLLYGFEVR PFFPCSRQPC PHVVDCFVSR PTEKTVFLLV MYVVSCLCLL LNLCEMAHLG LGSAQDAVRG RRGPPASAPA PAPRPPPCAF PAAAAGLACP PDYSLVVRAA ERARAHDQNL ANLALQALRD GAAAGDRDRD SSPCVGLPAA SRGPPRAGAP ASRTGSATSA GTVGEQGRPG THERPGAKPR AGSEKGSASS RDGKTTVWI
Explore Gap junction gamma-2 protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets